Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo

This article was originally published in The Tan Sheet

Executive Summary

David Gibbons is president, CEO effective May 1, company announces April 20. Gibbons, 56, has experience in consumer products and international management gleaned during two years as president of Rubbermaid Europe, two years as president of Rubbermaid Home Products and 27 years at 3M. The appointment should bring some continuity to the private labeler's upper management after an extended period of interim leadership. Gibbons succeeds Chairman Michael Jandernoa, who has served as CEO since 1986 and interim president since last November. Jandernoa took on the president role after Richard Hansen retired for a second time; Hansen had temporarily reassumed the position - a role he initially held from 1991 to 1995 - to help the firm implement its new software (1"The Tan Sheet" Nov. 15, 1999, p. 13)

You may also be interested in...



Perrigo Nicotine Patch Introduction Boosts First Quarter Sales Growth

The introduction of Perrigo's private label nicotine transdermal system helped the firm post strong sales and earnings growth for the first quarter ended Oct. 2, the company announced Nov. 9.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel